Transgender hormone therapy (female-to-male) to individuals taking bioidentical hormones in the form of testosterone (including esters) and do not apply to those taking synthetic AAS (e.g., nandrolone) or dihydrotestosterone. Transgender hormone therapy (female-to-male) Transgender hormone therapy of the female-to-male (FTM) type, also known as masculinizing hormone therapy, is a form of hormone therapy and sex reassignment therapy which is used to change the secondary sexual characteristics of transgender people from feminine (or androgynous) to masculine. It is one of two types of transgender hormone therapy (the other being male-to-female), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people
Fraternal birth order and male sexual orientation not non-biological older brothers predicted sexual orientation in men. Further, if rearing or social factors underlie the fraternal birth order effect, then the amount of time reared with older brothers, either biological or non-biological, should predict sexual orientation because rearing time determines the relative opportunity that older brothers have to affect their younger sibling's (postnatal) sociosexual development. If a prenatal factor underlies the fraternal birth order effect, then a postnatal factor such as rearing time with older siblings (be they biological or non-biological) should have no impact on the sexual orientation of younger male siblings. The study found that the